HomeCompareGHL vs ABBV

GHL vs ABBV: Dividend Comparison 2026

GHL yields 2.67% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $82.2K in total portfolio value
10 years
GHL
GHL
● Live price
2.67%
Share price
$14.99
Annual div
$0.40
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.1K
Annual income
$0.27
Full GHL calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GHL vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGHLABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GHL + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GHL pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GHL
Annual income on $10K today (after 15% tax)
$226.82/yr
After 10yr DRIP, annual income (after tax)
$0.23/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,055.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GHL + ABBV for your $10,000?

GHL: 50%ABBV: 50%
100% ABBV50/50100% GHL
Portfolio after 10yr
$61.2K
Annual income
$12,386.01/yr
Blended yield
20.23%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GHL
Analyst Ratings
3
Buy
8
Hold
6
Sell
Consensus: Hold
Price Target
$8.50
-43.3% upside vs current
Range: $7.00 — $10.00
Altman Z
0.8
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GHL buys
0
ABBV buys
0
No recent congressional trades found for GHL or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGHLABBV
Forward yield2.67%3.06%
Annual dividend / share$0.40$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$20.1K$102.3K
Annual income after 10y$0.27$24,771.77
Total dividends collected$269.00$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$8.50$256.15

Year-by-year: GHL vs ABBV ($10,000, DRIP)

YearGHL PortfolioGHL Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,833$133.42$11,550$430.00$717.00ABBV
2$11,659$67.54$13,472$627.96$1.8KABBV
3$12,509$33.97$15,906$926.08$3.4KABBV
4$13,402$17.03$19,071$1,382.55$5.7KABBV
5$14,349$8.53$23,302$2,095.81$9.0KABBV
6$15,357$4.27$29,150$3,237.93$13.8KABBV
7$16,435$2.13$37,536$5,121.41$21.1KABBV
8$17,586$1.07$50,079$8,338.38$32.5KABBV
9$18,818$0.53$69,753$14,065.80$50.9KABBV
10$20,135$0.27$102,337$24,771.77$82.2KABBV

GHL vs ABBV: Complete Analysis 2026

GHLStock

Greenhill & Co., Inc., an independent investment bank, provides financial and strategic advisory services to corporations, partnerships, institutional investors, and governments worldwide. The company offers advisory services related to mergers and acquisitions, divestitures, restructurings, financings, private capital raising, and other similar transactions. It also advises clients on strategic matters, including activist shareholder defense, special committee projects, licensing deals, and joint ventures; and valuation, negotiation tactics, industry dynamics, structuring alternatives, and timing and pricing of transactions, as well as financing alternatives. In addition, the company provides restructuring advisory services to debtors, creditors, governments, and other stakeholders, and acquirers of distressed companies and assets; and advice on restructuring alternatives, capital structures, and sales or recapitalizations. Further, it assists clients in identifying and capitalizing on incremental sources of value; and on court-assisted reorganizations by developing and seeking approval for plans of reorganization, as well as the implementation of such plans. Additionally, the company advises on private placements of debt and structured equity, refinancing of existing debt facilities, negotiating the modification, and amendment of covenants, as well as acts as an independent advisor. It also offers financial advisory services to pension funds, endowments, and other institutional investors on transactions involving alternative assets; and advice to alternative asset fund sponsors for private capital raising, financing, restructuring, liquidity options, valuation, and related services. The company was founded in 1996 and is headquartered in New York, New York.

Full GHL Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GHL vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GHL vs SCHDGHL vs JEPIGHL vs OGHL vs KOGHL vs MAINGHL vs JNJGHL vs MRKGHL vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.